BioCentury | Sep 30, 2013
Clinical News

Lucanix belagenpumatucel-L: Phase III data

...endpoint of improving median OS vs. placebo plus BSC (20.3 vs. 17.8 months, HR=0.94, p=0.594). NovaRx...
...European Cancer Congress in Amsterdam. Lucanix has Fast Track designation in the U.S. for NSCLC. NovaRx Corp....
BioCentury | Sep 27, 2013
Clinical News

NovaRx's Lucanix misses NSCLC endpoint

...who have responded to, or have stable disease following one regimen of, first-line platinum-based chemotherapy. NovaRx...
...p=0.083). Data will be presented at the European Cancer Congress in Amsterdam on Sept. 28. NovaRx...
BioCentury | Jul 2, 2012
Finance

3Q Financial Markets Preview: Miles of milestones

...nitroglycerin lingual spray Angina pectoris due to coronary artery disease (CAD) Submit regulatory application 2H12 NovaRx Corp....
BioCentury | Jun 18, 2012
Product Development

Immune springboard

...III data events expected over the next couple of years include Kael-Gemvax Co. Ltd. ; NovaRx Corp....
...another Phase III trial is evaluating the product in advanced non-small cell lung cancer (NSCLC). NovaRx's...
...Gaithersburg, Md. Memorial Sloan-Kettering Cancer Center , New York, N.Y. Merck KGaA (Xetra:MRK), Darmstadt, Germany NovaRx Corp....
BioCentury | Sep 13, 2010
Company News

Ocimum management update

...Hired: Norrie Russell as president of Ocimum's Gene Logic subsidiary, formerly president and COO of NovaRx Corp. WIR...
BioCentury | Nov 16, 2009
Clinical News

Lucanix: Phase III amended

...to be eligible for enrollment. Lucanix has Fast Track designation in the U.S. for NSCLC. NovaRx Corp....
BioCentury | Apr 20, 2009
Product Development

Phase III cancer vaccines

...with Affitech A/S) GV1001 Vaccine targeting human telomerase reverse transcriptase (hTERT) Pancreatic cancer Ph III NovaRx Corp....
BioCentury | Dec 8, 2008
Company News

NovaRx management update

NovaRx Corp. , San Diego, Calif. Business: Cancer Hired: Norrie Russell as president and COO, formerly president and CEO of Kalos Therapeutics Inc. Transitioned: Executive Vice Chairman Habib Fakhrai to CSO WIR Staff cancer...
BioCentury | Dec 5, 2008
Company News

NovaRx names Russell president

...Cancer company NovaRx (San Diego, Calif.) hired Norrie Russell as president and COO. Previously, he was...
...as president and COO. Previously, he was president and CEO of Kalos (San Diego, Calif.). NovaRx...
BioCentury | Aug 25, 2008
Clinical News

Lucanix: Phase III started

...disease after a platinum-based chemotherapeutic. Lucanix has Fast Track designation in the U.S. for NSCLC. NovaRx Corp....
Items per page:
1 - 10 of 21
BioCentury | Sep 30, 2013
Clinical News

Lucanix belagenpumatucel-L: Phase III data

...endpoint of improving median OS vs. placebo plus BSC (20.3 vs. 17.8 months, HR=0.94, p=0.594). NovaRx...
...European Cancer Congress in Amsterdam. Lucanix has Fast Track designation in the U.S. for NSCLC. NovaRx Corp....
BioCentury | Sep 27, 2013
Clinical News

NovaRx's Lucanix misses NSCLC endpoint

...who have responded to, or have stable disease following one regimen of, first-line platinum-based chemotherapy. NovaRx...
...p=0.083). Data will be presented at the European Cancer Congress in Amsterdam on Sept. 28. NovaRx...
BioCentury | Jul 2, 2012
Finance

3Q Financial Markets Preview: Miles of milestones

...nitroglycerin lingual spray Angina pectoris due to coronary artery disease (CAD) Submit regulatory application 2H12 NovaRx Corp....
BioCentury | Jun 18, 2012
Product Development

Immune springboard

...III data events expected over the next couple of years include Kael-Gemvax Co. Ltd. ; NovaRx Corp....
...another Phase III trial is evaluating the product in advanced non-small cell lung cancer (NSCLC). NovaRx's...
...Gaithersburg, Md. Memorial Sloan-Kettering Cancer Center , New York, N.Y. Merck KGaA (Xetra:MRK), Darmstadt, Germany NovaRx Corp....
BioCentury | Sep 13, 2010
Company News

Ocimum management update

...Hired: Norrie Russell as president of Ocimum's Gene Logic subsidiary, formerly president and COO of NovaRx Corp. WIR...
BioCentury | Nov 16, 2009
Clinical News

Lucanix: Phase III amended

...to be eligible for enrollment. Lucanix has Fast Track designation in the U.S. for NSCLC. NovaRx Corp....
BioCentury | Apr 20, 2009
Product Development

Phase III cancer vaccines

...with Affitech A/S) GV1001 Vaccine targeting human telomerase reverse transcriptase (hTERT) Pancreatic cancer Ph III NovaRx Corp....
BioCentury | Dec 8, 2008
Company News

NovaRx management update

NovaRx Corp. , San Diego, Calif. Business: Cancer Hired: Norrie Russell as president and COO, formerly president and CEO of Kalos Therapeutics Inc. Transitioned: Executive Vice Chairman Habib Fakhrai to CSO WIR Staff cancer...
BioCentury | Dec 5, 2008
Company News

NovaRx names Russell president

...Cancer company NovaRx (San Diego, Calif.) hired Norrie Russell as president and COO. Previously, he was...
...as president and COO. Previously, he was president and CEO of Kalos (San Diego, Calif.). NovaRx...
BioCentury | Aug 25, 2008
Clinical News

Lucanix: Phase III started

...disease after a platinum-based chemotherapeutic. Lucanix has Fast Track designation in the U.S. for NSCLC. NovaRx Corp....
Items per page:
1 - 10 of 21